Search - tctmd.com

Displaying 1 - 20 of 106

Sort: Relevancy | Date

Presentation TCT 2024

TCT 915: Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial

Presenter: Pieter Smits

October 30, 2024

Presentation TCT 2024

Future Metallic Drug Eluting Stents: New Designs, Platforms, and Components

Presenter: Pieter Smits

October 30, 2024

Presentation TCT 2024

TCT 130: Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: LANDMARK Trial

Presenter: Pieter Smits

October 29, 2024

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

Presentation TCT 2023

Beyond LDL

Presenter: Pieter Smits

October 26, 2023

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Presentation TCT 2022

Does It Matter What Stent I Use in a HBR Patient?

Presenter: Pieter Smits

September 18, 2022

Presentation TCT 2021

Case-Based Learning: Managing Non-culprit Lesions in the STEMI Patient With Coronary Physiology

Presenter: Pieter Smits

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

Presentation TCT 2019

Not So Fast: There Is So Much More to Learn!

Presenter: Pieter Smits

September 26, 2019

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

Presentation TCT 2018

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Presenter: Felix Mahfoud, Patrick W. Serruys, Pieter C. Smits

September 25, 2018

Presentation TCT 2018

Case Presentation #2: A High-Risk, Complex Patient With STEMI and Multivessel Disease

Presenter: Anthony H. Gershlick, Pieter C. Smits, Marwan F. Jumean

September 24, 2018

Presentation TCT 2018

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

Presenter: Anthony H. Gershlick, Pieter C. Smits, Deepak L. Bhatt

September 24, 2018

Presentation TCT 2018

Flash Debate #1: Based on What We Know - Routine Multivessel Revascularization (Acute or Delayed) Is the Preferred Strategy!

Presenter: Anthony H. Gershlick, Pieter C. Smits, Thomas Engstrøm

September 24, 2018

Presentation TCT 2018

The Role of FFR, iFR, and iMR in Assessing Non-Culprit Lesions and Vessels in STEMI

Presenter: Anthony H. Gershlick, Pieter C. Smits, Joo Myung Lee

September 24, 2018

Presentation TCT 2018

Management of Non-Culprit CTO in STEMI

Presenter: Anthony H. Gershlick, Pieter C. Smits, Emmanouil S. Brilakis

September 24, 2018

Advertisement

TCT 915: Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial

Future Metallic Drug Eluting Stents: New Designs, Platforms, and Components

TCT 130: Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: LANDMARK Trial

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Beyond LDL

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Does It Matter What Stent I Use in a HBR Patient?

Case-Based Learning: Managing Non-culprit Lesions in the STEMI Patient With Coronary Physiology

More DAPT Duration Data, More Calls to Tailor to Individual Patients

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Not So Fast: There Is So Much More to Learn!

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Case Presentation #2: A High-Risk, Complex Patient With STEMI and Multivessel Disease

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

Flash Debate #1: Based on What We Know - Routine Multivessel Revascularization (Acute or Delayed) Is the Preferred Strategy!

The Role of FFR, iFR, and iMR in Assessing Non-Culprit Lesions and Vessels in STEMI

Management of Non-Culprit CTO in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content